An analysis of pooled data from three Phase 3 clinical trials in idiopathic pulmonary fibrosis (IPF) patients shows that treatment with pirfenidone for one year significantly reduced disease progression. The study, titled “Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational…
IPF Patients Benefit from Pirfenidone Treatment
https://www.youtube.com/watch?v=yrFFDg04PCk Rose McGowan and her father were best friends. A few years ago he started to experience shortness of breath, a dry cough and swelling on his fingers; he had several misdiagnoses until he finally got the news that he was suffering from pulmonary fibrosis. Rose is now an ambassador for Coalition…
In this video from MUSC Health, shared in 2013, meet Jimi Beauston, a patients diagnosed with idiopathic pulmonary fibrosis in 2011. Watch the video to know more about his story and how a lung transplant changed his life. Learn more about Lung Transplant…
Lebrikizumab is an experimental drug aimed at treating inflammatory and fibrotic diseases. Owing to its immunosuppressive potential, it has been tested against diseases like asthma and refractory Hodgkin’s Lymphoma with successful results. Currently, the company is also pursuing studies to test its use in Idiopathic Pulmonary Fibrosis. Lebrikizumab was first…
DS Biopharma, headquartered in Dublin, Ireland, and focused on therapies for inflammatory and fibrotic skin and pulmonary disorders, recently announced that a Phase 1 clinical trial evaluating safety and dosing levels for its drug candidate DS102 (15-HEPE) has been successfully completed. DS102 is an oral bioactive lipid drug developed as…
“This is John’s story. A true story. A day by day account of his life as told by himself in a series called – Emphysema Man. Proof positive that, with the exception of death and taxes, there are no guarantees in life.” Learn more about Emphysema: https://bit.ly/1ONmRdG…
Read the articles: 1. Idiopathic Pulmonary Fibrosis Trial to Test Combination of Existing Treatments 2. IPF Study Focuses on Patient and Caregiver Needs Beyond Treatment 3. IPF Patients Seen to Benefit from Pirfenidone Treatment…
“David Flurett was diagnosed with IPF – an incurable disease that causes scarring of the lungs. His doctors put him on a lung transplant list. On May 18, 2014 he received a lung transplant at MUSC.” Read more about Pulmonary Fibrosis: https://bit.ly/1lfMsiZ Learn more about Lung Transplants: https://bit.ly/1SNRT3u…
https://www.youtube.com/watch?v=FrPNIFjLgRw “Dr Toby Maher of the Royal Brompton Hospital, UK, talks about the impact of idiopathic pulmonary fibrosis (IPF) and the need to shed light on this ‘invisible disease’ .” Learn more about IPF:Â https://bit.ly/1QiRmr3…
A potentially important new study, published in the Journal of Biological Chemistry, identified fibroblast activation protein (FAP) as a crucial factor in collagen fragment clearance in the lungs. Clearing collagen fragments is a key step in reducing tissue scarring and restoring lung function following injury, making FAP an interesting target…
